0001127602-23-006580.txt : 20230222
0001127602-23-006580.hdr.sgml : 20230222
20230222205117
ACCESSION NUMBER: 0001127602-23-006580
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Sean C.
CENTRAL INDEX KEY: 0001801993
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 23655623
MAIL ADDRESS:
STREET 1: C/O VERICEL CORPORATION
STREET 2: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-02-17
0000887359
Vericel Corp
VCEL
0001801993
Flynn Sean C.
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE
MA
02139
1
SVP, General Counsel
Common Stock
2023-02-18
4
M
0
2325
0
A
6413
D
Common Stock
2023-02-18
4
F
0
1155
29.82
D
5258
D
Common Stock
2023-02-19
4
M
0
1750
0
A
7008
D
Common Stock
2023-02-19
4
F
0
832
29.82
D
6176
D
Stock Option
(Right to Buy)
29.82
2023-02-17
4
A
0
1875
0
A
2033-02-17
Common Stock
1875
1875
D
Stock Option
(Right to Buy)
29.82
2023-02-17
4
A
0
28125
0
A
2033-02-17
Common Stock
28125
28125
D
Restricted Stock Unit
2023-02-17
4
A
0
12000
0
A
Common Stock
12000
12000
D
Restricted Stock Unit
2023-02-18
4
M
0
2325
D
Common Stock
2325
6975
D
Restricted Stock Unit
2023-02-19
4
M
0
1750
D
Common Stock
1750
3500
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024, and February 19, 2025.
These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
No expiration date for this type of award.
The Fair Market Value of the vested derivative securities is $29.82 per share.
/s/ Sean Flynn
2023-02-22